Oocyte Cryopreservation Registry (HOPE Registry)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00699400
Recruitment Status : Completed
First Posted : June 18, 2008
Results First Posted : January 24, 2014
Last Update Posted : January 24, 2014
Information provided by (Responsible Party):
EMD Serono

June 13, 2008
June 18, 2008
May 16, 2013
January 24, 2014
January 24, 2014
June 2008
May 2012   (Final data collection date for primary outcome measure)
Thawing Cycle Level Live Birth Rate [ Time Frame: Birth of one or more live babies ]
Live birth rate per thawing cycle was calculated from the number of live births divided by the number of oocytes thawed less the number of embryos cryopreserved from thawed oocytes, averaged over all thawing cycles.
Prospectively register and track the outcomes of cycles with frozen-thawed oocytes that are fertilized and transferred in subjects [ Time Frame: Multiple timepoints ]
Complete list of historical versions of study NCT00699400 on Archive Site
  • Oocyte Level Live Birth Rate [ Time Frame: Birth of one or more live babies ]
    Oocyte Level Live Birth Rate was calculated from the total number of live births divided by the total number of oocytes thawed less the total number of embryos cryopreserved from thawed oocytes
  • Number of Live Babies [ Time Frame: Birth of one or more live babies ]
  • Number of Oocytes Frozen [ Time Frame: At cryopreservation ]
  • Number of Oocytes Thawed [ Time Frame: At start of thawing cycle ]
  • Oocyte Survival Rate [ Time Frame: At time of fertilization ]
    Number of oocytes fertilized divided by number of oocytes thawed per thawing cycle
  • Implantation Rate [ Time Frame: At time of ultrasound after embryo transfer ]
    Implantation rate was calculated as the number of fetal sacs per transferred embryo averaged over all thawing cycles
  • Number of Clinical Pregnancies [ Time Frame: At time of ultrasound after embryo transfer ]
    Number of clinical pregnancies defined as the presence of one or more fetal sacs with a heartbeat.
  • Number of Miscarriages [ Time Frame: Anytime after embryo transfer ]
    Number of pregnancy outcomes reported as spontaneous abortions
Identify factors associated with successful cycle outcomes and to monitor the child's health and development immediately after birth and at twelve (12) months of age, utilizing standard medical practices. [ Time Frame: Multiple timepoints ]
Not Provided
Not Provided
Oocyte Cryopreservation Registry (HOPE Registry)
A Phase IV, Prospective, Multicenter, Observational Oocyte Cryopreservation Registry
Phase IV, prospective multicenter, observational Registry will track cycle outcomes for subjects who are thawing frozen oocytes for subsequent use through in vitro fertilization (IVF) and embryo transfer (ET)
Subjects will be enrolled at as many ART clinics that offer oocyte cryopreservation and are willing to participate in the Registry. Oocytes will be retrieved and cryopreserved from autologous or heterologous donors. When the subject decides she would like to get pregnant, oocytes will be thawed, fertilized and the resultant embryos will be transferred to the oocyte donor (for autologous use) or to another recipient (for heterologous use). The treatment regimen will be completed with births and well-baby follow-up of children at 12 months of age. Information on children will be submitted by their parents to the Investigators. Data collection for the Registry will be active for a maximum of five (5) years, including three (3) years of enrollment and two (2) additional years to complete the well-baby follow-up for all the children.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Women of reproductive age who, in order to achieve a pregnancy, will have embryos created from thawed autologously or heterologously implanted oocytes that were either:

  • cryopreserved at the time of or following the Registry's launch, or
  • cryopreserved prior to the Registry's launch, but will undergo thaw/fertilization/transfer procedures while the subject is enrolled in the Registry.
Oocyte Cryopreservation
Not Provided
Not Provided
Nagy ZP, Anderson RE, Feinberg EC, Hayward B, Mahony MC. The Human Oocyte Preservation Experience (HOPE) Registry: evaluation of cryopreservation techniques and oocyte source on outcomes. Reprod Biol Endocrinol. 2017 Feb 7;15(1):10. doi: 10.1186/s12958-017-0228-7.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2012
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must be in an ART program
  • Donor and recipients must be of reproductive age (18-50 years old, inclusive at the time of oocyte freezing and/or thawing) who intend to achieve a pregnancy by utilizing frozen thawed autologous or heterologous oocytes
  • Female and partner (if applicable) must voluntarily provide written informed consent/HIPAA authorization prior to any Registry-related data collection
  • Female and partner (if applicable) must be willing to provide a second written informed consent following each live birth prior to any Registry- related data collection on birth characteristics and twelve (12) month evaluation of offspring
  • Children born from women who take part in this registry from birth to 12 months (+/- 1 month) of age

Exclusion Criteria:

  • Have clinically significant systemic disease
  • Have abnormal, undiagnosed gynecological bleeding
  • Have any contraindication to Controlled Ovarian Stimulation (COS) for ART and to gonadotropins to be used in ART
  • Also, in a rare situation, are undergoing ET with mixed embryos generated from fresh oocytes produced in the current cycle as well as frozen embryos generated from nonfrozen oocytes obtained in a previous ART cycle
  • Children born from women who do not take part in this Registry
  • Any offspring of woman who are not Registry subjects cannot take part in this registry
Sexes Eligible for Study: Female
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
EMD Serono
EMD Serono
Not Provided
Study Director: Mary Mahony, PhD, HCLD (AAB) EMD Serono
EMD Serono
December 2013